Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Get Free Report) reached a new 52-week high during trading on Wednesday . The company traded as high as $54.85 and last traded at $53.73, with a volume of 41095 shares. The stock had previously closed at $53.26.
Wall Street Analyst Weigh In
TARS has been the topic of several analyst reports. The Goldman Sachs Group lifted their price target on shares of Tarsus Pharmaceuticals from $36.00 to $41.00 and gave the company a "neutral" rating in a report on Friday, November 15th. Oppenheimer lifted their target price on shares of Tarsus Pharmaceuticals from $63.00 to $65.00 and gave the company an "outperform" rating in a research note on Thursday, November 14th. Finally, William Blair upgraded Tarsus Pharmaceuticals to a "strong-buy" rating in a research note on Friday, August 30th. One analyst has rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of "Buy" and a consensus price target of $54.20.
Check Out Our Latest Research Report on TARS
Tarsus Pharmaceuticals Trading Down 1.1 %
The stock has a market cap of $2.01 billion, a P/E ratio of -13.83 and a beta of 1.04. The stock's 50-day moving average is $45.83 and its two-hundred day moving average is $34.76. The company has a debt-to-equity ratio of 0.30, a current ratio of 5.42 and a quick ratio of 5.38.
Institutional Inflows and Outflows
Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Quest Partners LLC purchased a new stake in shares of Tarsus Pharmaceuticals in the second quarter worth about $61,000. Canada Pension Plan Investment Board bought a new position in shares of Tarsus Pharmaceuticals during the 2nd quarter valued at approximately $114,000. Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in shares of Tarsus Pharmaceuticals by 33.4% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 6,109 shares of the company's stock valued at $166,000 after purchasing an additional 1,530 shares in the last quarter. FMR LLC increased its position in Tarsus Pharmaceuticals by 236.6% in the third quarter. FMR LLC now owns 5,032 shares of the company's stock worth $166,000 after purchasing an additional 3,537 shares during the last quarter. Finally, Dark Forest Capital Management LP purchased a new stake in Tarsus Pharmaceuticals during the second quarter valued at $202,000. Institutional investors own 90.01% of the company's stock.
About Tarsus Pharmaceuticals
(
Get Free Report)
Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.
Read More
Before you consider Tarsus Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Tarsus Pharmaceuticals wasn't on the list.
While Tarsus Pharmaceuticals currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
